Sarah Emond

It can't be that we continue to just be price takers from the ecosystem without any conversation about whether or not the price is fair or we won't have money to pay for these innovations in the future.

That's Sarah Emond, President and CEO of ICER, the Institute for Clinical and Economic Review.

joining us to provide an update on the market for cell and gene therapies, some of healthcare's most innovative and costly treatments.

I'm Ellen Kelsey, and this is the Business Group on Health podcast, conversations with experts on the most relevant health and well-being issues facing employers.

It's been an absolute pleasure, Ellen.

Thank you for having me back.

I've been speaking with Sarah Emond about the evolving challenges and developments and what employers should be watching as the next generation of saline gene therapies comes to market.

I'm Ellen Kelsey, and this podcast is produced by Business Group on Health with Connected Social Media.